Provention Bio to Report Second Quarter 2020 Financial Results and Host Conference Call on Thursday, August 6, 2020

Rhea-AI Summary

Provention Bio, Inc. (Nasdaq: PRVB) will release its second quarter 2020 financial results on August 6, 2020. A live conference call will occur at 8:00 AM ET to discuss these results and provide a business update. The company focuses on preventing immune-mediated diseases, with its leading candidate, teplizumab, aimed at delaying insulin-dependent type 1 diabetes. Provention's strategy emphasizes developing therapeutics for autoimmune diseases with significant healthcare implications.

Positive

• The upcoming earnings report may provide insights into financial performance.
• Provention is advancing teplizumab, showing promise in delaying insulin-dependent type 1 diabetes.

Negative

• None.

OLDWICK, N.J., July 30, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its second quarter 2020 financial results on Thursday, August 6, 2020.

In connection with the earnings release, Provention's management team will host a live conference call and webcast at 8:00 AM ET on Thursday, August 6, 2020, to discuss the Company's financial results and provide a business update.

Conference Call Information
To access the call, please dial 1-888-567-1603 (domestic) or 1-862-298-0702 (international) five minutes prior to the start time and ask to be connected to the "Provention Bio Call." An audio webcast will also be available on the "Events and Webcasts" page of the Investors section of the Company's website, www.proventionbio.com.  An archived webcast will be available on the Company's website approximately two hours after the conference call and will be available for seven days following the call. 

About Provention Bio, Inc.
Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company leveraging a transformational drug development strategy focused on the prevention or interception of immune-mediated disease. Provention's mission is to source, transform and develop therapeutic candidates targeting the high morbidity, mortality and escalating costs of autoimmune diseases. Provention's diversified portfolio includes teplizumab, a pre-commercial-stage candidate that has been shown to delay the onset of insulin-dependent type 1 diabetes (T1D) in at-risk patients during the presymptomatic phase of the disease. The Company's portfolio includes additional clinical product development candidates that have demonstrated proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus.

Investors:
Sam Martin, Argot Partners
sam@argotpartners.com   
212-600-1902

Media:
Lori Rosen, LDR Communications
lori@ldrcommunications.com 
917-553-6808

View original content to download multimedia:http://www.prnewswire.com/news-releases/provention-bio-to-report-second-quarter-2020-financial-results-and-host-conference-call-on-thursday-august-6-2020-301102826.html

SOURCE Provention Bio, Inc.

FAQ

When will Provention Bio report its second quarter 2020 earnings?

Provention Bio will report its second quarter 2020 financial results on August 6, 2020.

What time is the Provention Bio conference call?

The conference call will take place at 8:00 AM ET on August 6, 2020.

What is the main focus of Provention Bio?

Provention Bio focuses on intercepting and preventing immune-mediated diseases, particularly through its candidate teplizumab for type 1 diabetes.